Pembrolizumab monotherapy in heavily treated recurrent cervical cancer patients: case series report

Abstract

This study aimed to evaluate the effectiveness of pembrolizumab among patients with recurrent cervical cancer. We retrospectively reviewed the medical records of patients diagnosed with recurrent cervical cancer and treated with pembrolizumab. Fixed does of pembrolizumab 200 mg was administered intravenously every three weeks. The primary endpoint was the objective response rate. In total, 14 patients were included in this study. Median number of pembrolizumab cycles was five (range, 1–28). The objective response rate was 28.6%, with one complete response and three partial responses. The treatment was generally well tolerated. None of the patients experienced treatment discontinuation or treatment-related death due to adverse events. Pembrolizumab monotherapy showed modest antitumor activity against recurrent cervical cancer. Pembrolizumab monotherapy is an alternative treatment option for patients with recurrent cervical cancer.